Brooks Laboratories Ltd

NSE: BROOKS · BSE: 533543 · Pharmaceuticals & Biotechnology · 19 announcements

Share price: ₹58.51
Market cap: ₹172.3 Cr
Revenue (annual): ₹85.74 Cr
Net profit (annual): ₹24.58 Cr
P/E (TTM): 13.1×Sector 47.4×
Promoter holding: 52.62%+0.00% QoQ
FII holding: 0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Other Announcement 4 Management Change 3 Financial Results 3 Annual General Meeting 3 Merger & Restructuring 2 Board Meeting Date 2 Debt & Borrowing 1 Adverse Business Impact 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

2 announcements with these filters

16 Jul 2026 18:26 IST BSE

Merger & Restructuring

Brooks Laboratories Merger & Restructuring Worth ₹106.3 Cr

Brooks Laboratories signed a binding MoU to sell a portion of its Brooks Steriscience stake. The deal provides Rs.106.33 Crore cash inflow and retains 32.67% equity.

Value: ₹106.3 Cr
Execution: 2 years

Read the filing ↗

2 Jul 2026 18:30 IST BSE

Merger & Restructuring

Brooks Laboratories Merger & Restructuring

Brooks Laboratories Ltd incorporated a wholly owned subsidiary, Abridge Speciality Limited. This strategic move aims to expand its pharmaceutical business operations.

Read the filing ↗